R(+)-6-Bromo-APB HBr | CAS#139689-19-3 | Dopamine receptor agonist

MedKoo Cat#: 563376 | Name: R(+)-6-Bromo-APB HBr

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

R(+)-6-Bromo-APB HBr is a potent D1 Dopamine receptor agonist.

Chemical Structure

R(+)-6-Bromo-APB HBr

CAS#139689-19-3

Theoretical Analysis

MedKoo Cat#: 563376

Name: R(+)-6-Bromo-APB HBr

CAS#: 139689-19-3

Chemical Formula: C19H21Br2NO2

Exact Mass:

Molecular Weight: 455.19

Elemental Analysis: C, 50.13; H, 4.65; Br, 35.11; N, 3.08; O, 7.03

Price and Availability

Size	Price	Availability	Quantity
25mg	USD 620.00	2 weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

R(+)-6-Bromo-APB hydrobromide; R(+) 6 Bromo APB hydrobromide; R(+)-6-Bromo-APB HBr; R(+) 6 Bromo APB HBr;

IUPAC/Chemical Name

(R)-3-allyl-6-bromo-1-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine-7,8-diol hydrobromide

InChi Key

CTAUBYSSTAODOD-PKLMIRHRSA-N

InChi Code

InChI=1S/C19H20BrNO2.BrH/c1-2-9-21-10-8-14-15(11-17(22)19(23)18(14)20)16(12-21)13-6-4-3-5-7-13;/h2-7,11,16,22-23H,1,8-10,12H2;1H/t16-;/m1./s1

SMILES Code

OC1=C(O)C=C2[C@@H](C3=CC=CC=C3)CN(CC=C)CCC2=C1Br.Br

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

R(+)-6-Bromo-APB HBr is a salt.

In vitro activity:

Dopaminergic D1/D5-receptor-mediated processes are important for certain forms of memory. The short-term application of D1/D5-receptor agonists (one of which was R(+)-6-Bromo-APB HBr) can induce a slow-onset potentiation. Reference: Neuropharmacology. 2007 Jun;52(7):1547-54. doi: https://pubmed.ncbi.nlm.nih.gov/17433377/

In vivo activity:

Continuous cocaine administration has been shown to upregulate the level of mu opioid receptor (MOR) mRNA in the nucleus accumbens of rat brains. Dopamine antagonists and agonists, one agonist being R(+)-6-bromo-APB hydrobromide, mimicked the cocaine-induced upregulation of MOR mRNA, suggesting involvement of both subfamilies of DA receptors in the effect of cocaine. Reference: Can J Physiol Pharmacol. 1998 Mar;76(3):278-83. https://pubmed.ncbi.nlm.nih.gov/9673791/

Preparing Stock Solutions

The following data is based on the product molecular weight 455.19 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Navakkode S, Sajikumar S, Frey JU. Synergistic requirements for the induction of dopaminergic D1/D5-receptor-mediated LTP in hippocampal slices of rat CA1 in vitro. Neuropharmacology. 2007 Jun;52(7):1547-54. doi: 10.1016/j.neuropharm.2007.02.010. Epub 2007 Mar 12. PMID: 17433377. 2. Azaryan AV, Clock BJ, Rosenberger JG, Cox BM. Transient upregulation of mu opioid receptor mRNA levels in nucleus accumbens during chronic cocaine administration. Can J Physiol Pharmacol. 1998 Mar;76(3):278-83. PMID: 9673791. 3. Azaryan AV, Clock BJ, Cox BM. Mu opioid receptor mRNA in nucleus accumbens is elevated following dopamine receptor activation. Neurochem Res. 1996 Nov;21(11):1411-5. doi: 10.1007/BF02532382. PMID: 8947931.

In vitro protocol:

To be determined1. Navakkode S, Sajikumar S, Frey JU. Synergistic requirements for the induction of dopaminergic D1/D5-receptor-mediated LTP in hippocampal slices of rat CA1 in vitro. Neuropharmacology. 2007 Jun;52(7):1547-54. doi: 10.1016/j.neuropharm.2007.02.010. Epub 2007 Mar 12. PMID: 17433377.

In vivo protocol:

To b1. Azaryan AV, Clock BJ, Rosenberger JG, Cox BM. Transient upregulation of mu opioid receptor mRNA levels in nucleus accumbens during chronic cocaine administration. Can J Physiol Pharmacol. 1998 Mar;76(3):278-83. PMID: 9673791. 2. Azaryan AV, Clock BJ, Cox BM. Mu opioid receptor mRNA in nucleus accumbens is elevated following dopamine receptor activation. Neurochem Res. 1996 Nov;21(11):1411-5. doi: 10.1007/BF02532382. PMID: 8947931.e determined

1: Navakkode S, Sajikumar S, Frey JU. Synergistic requirements for the induction of dopaminergic D1/D5-receptor-mediated LTP in hippocampal slices of rat CA1 in vitro. Neuropharmacology. 2007 Jun;52(7):1547-54. Epub 2007 Mar 12. PubMed PMID: 17433377. 2: Mockett BG, Brooks WM, Tate WP, Abraham WC. Dopamine D1/D5 receptor activation fails to initiate an activity-independent late-phase LTP in rat hippocampus. Brain Res. 2004 Sep 17;1021(1):92-100. PubMed PMID: 15328036. 3: Azaryan AV, Clock BJ, Rosenberger JG, Cox BM. Transient upregulation of mu opioid receptor mRNA levels in nucleus accumbens during chronic cocaine administration. Can J Physiol Pharmacol. 1998 Mar;76(3):278-83. PubMed PMID: 9673791. 4: Sun MH, Ishine T, Lee TJ. Dopamine constricts porcine pial veins. Eur J Pharmacol. 1997 Sep 10;334(2-3):165-71. PubMed PMID: 9369345. 5: Azaryan AV, Clock BJ, Cox BM. Mu opioid receptor mRNA in nucleus accumbens is elevated following dopamine receptor activation. Neurochem Res. 1996 Nov;21(11):1411-5. PubMed PMID: 8947931.